News

Micronized Diosmin and Flavonoid Fraction – What Do They Have in Common?
Micronized diosmin and micronized purified flavonoid fraction are medications from the flavonoid group that are used as venopharmaceuticals/venoprotectives in the treatment of chronic venous insufficiency and hemorrhoidal disease. Both have many common properties, which we discuss in the following text. Their differences will be covered in a follow-up article on this topic.

Do antiglaucoma drugs induce inflammation and irritation on the eye surface? Results of a 2-year randomized study
Eye drops for glaucoma treatment may contain preservatives responsible for eye irritation and…

Antiglaucoma Eye Drops with Preservatives – Higher Likelihood of Glaucoma Surgery?
A recently published French study sought to answer the question of whether there is a connection…

Quantitative CT as a New Tool for Evaluating COPD in Alpha-1 Antitrypsin Deficiency
For such a rare hereditary disorder as alpha-1 antitrypsin deficiency (AATD), we have so far used…

Intravenous Thrombolysis in Ischemic Stroke Patients on Dabigatran Treatment
What are the outcomes of performing intravenous thrombolysis in patients with acute ischemic stroke…

Lactobacillus reuteri − a natural probiotic with lifelong significance
Probiotics are often given to newborns within the first few days of life to alleviate infantile…

State of the Intestinal Microbiome and COVID-19 Infection − Possible Correlations
Some patients infected with the SARS-CoV-2 virus exhibit gastrointestinal symptoms, including…

Safety Profile of Antiemetic Therapy in Patients Preparing for Hematopoietic Stem Cell Transplantation
An observational study conducted at a university clinic in Barcelona investigated the safety of the…

Intravenous Fixed Combination NEPA in the Prevention of Chemotherapy-Induced Vomiting
Summary data from several studies were used by the authors of the following analysis to evaluate…

Brigatinib vs. Crizotinib in the Treatment of ALK-Positive NSCLC – Results of the Second Interim Analysis of the ALTA-1L Study
The anaplastic lymphoma kinase inhibitor brigatinib demonstrated superiority over crizotinib in the…